key: cord-0683369-khk9z9kb
authors: Rosales-Castillo, Antonio; Sabio, José Mario
title: Assessment of antiphospholipid antibodies during the follow-up of patients after SARS-CoV-2 infection
date: 2022-04-14
journal: Med Clin (Engl Ed)
DOI: 10.1016/j.medcle.2021.09.015
sha: 4d67cd3af780e59ba4688c47134079f4ea13e805
doc_id: 683369
cord_uid: khk9z9kb

nan

To the Editor: Since its emergence at the end of 2019, the pathophysiology and clinical presentation of SARS-CoV-2 infection is becoming increasingly well understood as time goes by 1 . One aspect to consider is the possible association with antiphospholipid antibodies, due to growing evidence of its association with an increased systemic prothrombotic effect. There are studies on the determination of these antibodies during the acute phase of infection 2,3 ; however, the aim of our study is to determine the presence of these antibodies in patients who have overcome the infection and the persistence or disappearance of these antibodies during follow-up.

A specialist consultation follow-up was carried out on 189 patients admitted to the inpatient ward of the Hospital Virgen de las Nieves in Granada between March and October 2020, all of them with confirmed SARS-CoV-2 infection by PCR or serology, excluding unconfirmed suspects. In addition to the clinical and radiological reevaluation, lupus anticoagulant and antiphospholipid antibodies (anti-cardiolipin IgM and IgG; anti-beta2 glycoprotein IgM and IgG) were determined in 2░cut-off values. The cut-off value for lupus anticoagulant positivity was set at 1.2 in at least one of the tests used in our hospital laboratory (Russell's viper venom test and activated partial thromboplastin); antiphospholipid antibodies were divided into weak (10-40 IU/ml) and strong (> 40 IU/ml) positivity. 

The results of the 2░determinations are shown schematically in table 1. The first was performed on average 89 days after a PCR positive result and the second after 180 days.

It is noteworthy that these antibodies remain positive 6 months after acute SARS-CoV-2 infection, even with high titres. In addition, 3 patients with triple positivity (lupus anticoagulant, anticardiolipin, and anti-beta2 glycoprotein) and 3 patients with double positivity (combination of 2░of them) were observed.

Another aspect that we consider important is the higher prevalence of positive results for lupus anticoagulant, anticardiolipin-IgM and anti-beta2 glycoprotein (IgM and IgG) in men, with a greater difference than in women for lupus anticoagulant at 180 days.

During the follow-up of these patients no thromboembolic events have been observed after hospital discharge, so the potential pathogenic role of these antibodies is still unknown. We do not know whether, in the future, a percentage of them will meet criteria for antiphospholipid syndrome and develop thrombotic events 4 , or whether it is a transient immune reaction associated with the viral infection itself 5 . 

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan

Lupus anticoagulant and mortality in patients hospitalized for COVID-19

Antiphospholipid antibodies in critically ill patients with COVID-19

Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome

Infections and autoimmunity-Friends or foes?

The authors declare that they have no conflict of interest.